Clinical trials: Classical Hodgkin Lymphoma, open to volunteers
Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
This phase II trial tests how well tafasitamab and rituximab works for the treatment of newly diagnosed follicular lymphoma. Tafasitamab is a monoclonal antibody.
- Conditions
- Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
- Trial name
- NCT07731789
- Testing
- Rituximab, Tafasitamab, Biospecimen Collection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
This phase II trial studies the effect of brentuximab vedotin and nivolumab in treating patients with classic Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory) that have been previously…
- Trial name
- NCT05039073
- Testing
- Brentuximab Vedotin, Hematopoietic Cell Transplantation, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Emory University
Hodgkin Lymphoma
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
The main aim of this study is to check how safe brentuximab vedotin is in adults with untreated Hodgkin Lymphoma (HL) when given together with doxorubicin (Adriamycin), vinblastine and dacarbazine therapy ('AVD').
- Trial name
- NCT06831370
- Testing
- Brentuximab Vedotin, Doxorubicin, Vinblastine
- Where
- 11 sites in India
- Volunteers
- 124 people
- Sponsor
- Takeda
Hodgkin Lymphoma
Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
The goal of this clinical research study is to learn if nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) can help to control newly diagnosed early-stage non-bulky cHL in pediatric, adolescent, and young adult…
- Trial name
- NCT07551583
- Testing
- Nivolumab, Doxorubicin Hydrochloride, Vinblastine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Classic Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
Neurocognitive Assessment in Long-Term Survivors of Lymphoma
This is an observational, multicenter, prospective cohort study including patients treated for lymphoma in Italian real-life. Patients eligible for the enrollment in the study will be consecutively included in Italian FIL…
- Conditions
- Classic Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal B Cell Lymphoma
- Trial name
- FIL_LymDeCo (NCT07652476)
- Testing
- anthracycline containing regimen
- Where
- 7 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Classical Hodgkin Lymphoma
Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma
The aim of this trial is to develop an effective and well-tolerated regimen for treatment of r/r cHL by introducing the anti-PD-1 antibody pembrolizumab and adding it to well-established chemotherapy regimens (ICE, DHAP).
- Trial name
- Pembro-CORE (NCT04838652)
- Testing
- Pembrolizumab plus Chemotherapy (ICE or DHAP)
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- University of Cologne
Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B
Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment
The aim of this multicenter, non-randomized, cluster controlled trial study is to evaluate the impact of a geriatric-guided approach with a pro-active rehabilitative/nutritional plan for elderly unfit/frail DLBCL patients…
- Trial name
- NCT07476105
- Testing
- Geriatric-guided supportive care, Conventional supportive care
- Where
- 24 sites in Italy
- Volunteers
- 170 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma
Immunotherapy in Lymphoma
The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed/refractory high grade B cell lymophoma patients.
- Conditions
- Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma Relapsed, Primary Mediastinal Large B-Cell Lymphoma
- Trial name
- NCT06796517
- Testing
- CAR-T Therapy, Bispecific antibody, Antibody-Drug Conjugate
- Where
- 2 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Sung-Soo Park
Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
This is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year.
- Trial name
- NCT06377540
- Testing
- Pembrolizumab, Autologous stem cell transplant, Carmustine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Classic Hodgkin Lymphoma
A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma
The purpose of this study is to compare efficacy of IMM01 plus Tiselizumab with physician's choice chemotherapy of bendamustine or gemcitabine in participants with PD-(L)1-refractory classical Hodgkin Lymphoma.
- Trial name
- NCT06465446
- Testing
- Tislelizumab, IMM01, Bendamustine
- Volunteers
- 202 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Classical Hodgkin Lymphoma
Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma
By the implementation of the anti-PD-1 antibody pembrolizumab and given its possible synergy with RT, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients with newly diagnosed…
- Trial name
- PREFer (NCT06916416)
- Testing
- Pembrolizumab
- Volunteers
- 50 people
- Sponsor
- University of Cologne
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
This is a prospective randomized open-label, multicenter, 2-arm study to assess the role of healthy LifeStyle implemented Survivorship Care Plan (LS-SCP) in modifying the Quality of Life (QoL) in a population of long-term…
- Conditions
- Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Trial name
- NCT05934084
- Testing
- Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
- Where
- 40 sites in Italy
- Volunteers
- 552 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer)
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from recognizing and destroying cancer cells.
- Conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer), Non-Small Cell Lung Cancer
- Trial name
- NCT07555210
- Testing
- Dual-Energy X-ray Absorptiometry (DXA), High Resolution peripheral Quantitative Computed Tomography (HRpQCT)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Jessica Mezzanotte Sharpe
Hodgkin Lymphoma (Category)
Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma
Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET/CT) in order to guide…
- Trial name
- BASTION (NCT06919679)
- Testing
- BrECADD
- Volunteers
- 35 people
- Sponsor
- University of Cologne
Cardiovascular Disorder, Classic Hodgkin Lymphoma
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
This study assesses how blood cell growth patterns (clonal hematopoiesis) relate to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma.
- Conditions
- Cardiovascular Disorder, Classic Hodgkin Lymphoma, Clonal Hematopoiesis
- Trial name
- NCT05705531
- Testing
- Archive Sample Retrieval, Biospecimen Collection, Electronic Health Record Review
- Where
- 36 sites in United States, Canada
- Volunteers
- 190 people
- Sponsor
- Children's Oncology Group
Hodgkin Lymphoma
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
The study is being conducted to compare JS004 plus Toripalimab with Investigator-Selected Chemotherapy in Patients with PD-(L)1 monoclonal antibody refractory Classic Hodgkin Lymphoma (cHL)
- Trial name
- NCT06170489
- Testing
- JS004 in combination with Toripalimab, Bendamustine or gemcitabine
- Where
- China
- Volunteers
- 185 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
This is a single arm, open-label, multicenter, phase II study of pembrolizumab (pembro), gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) in patients with relapsed or refractory classic Hodgkin lymphoma (cHL) with…
- Conditions
- Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma
- Trial name
- NCT07021989
- Testing
- Pembrolizumab, Non-investigational, involved site radiotherapy (ISRT), Gemcitabine
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- Michael Spinner, MD
Classic Hodgkin Lymphoma
A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
This is a phase I/II study. All subjects are patients diagnosed with relapse or refractory (R/R) classic Hodgkin lymphoma (cHL) and has progressed on treatment with PD-1/L1 inhibitor therapy.
- Trial name
- NCT06642792
- Testing
- AK129, AK117
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Akeso
Relapsed Classic Hodgkin Lymphoma
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment…
- Trial name
- NCT04561206
- Testing
- Brentuximab Vedotin, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Classical Hodgkins Lymphoma in Children and Adolescents.
Treatment for Classical Hodgkin Lymphoma in Children and Adolescents
Reduction of the indication for radiotherapy (RT) in newly diagnosed patients with classical Hodgkins lymphoma without compromising cure rates.
- Trial name
- EuroNet-PHL-C2 (NCT02797717)
- Testing
- Radiotherapy:, Vincristine, Etoposide
- Where
- Israel
- Volunteers
- 2,200 people
- Sponsor
- GALIA AVRAHAMI